Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CUE
Strong SellHot AirCue Biopharma, Inc. · Healthcare · United States · $203M · Avg Vol: $5M/d
16
StockRankGet insider-trade alerts
Q
12
V
23
M
63
P/E (TTM)
—
ROE
-1603.5%
D/E
1.3x
Dividend %
—
COMPANY DESCRIPTION
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2M | 5.5M | 9.3M | 27.5M | 180.5% | 37.7M | 16.6M | — | -39.5% |
| EPS | -15.27 | -12.48 | -10.60 | -8.40 | — | -29.46 | -21.46 | -6.83 | — |
| Shares | 4.2M | 4.2M | 4.2M | 3.2M | -23.3% | — | — | — | — |
| Debt | 19.3M | 14.7M | 8.9M | 4.2M | -39.9% | 3.1M | — | — | — |
| Equity | 65.7M | 37.1M | 17.5M | 26.4M | -26.2% | — | — | — | — |
| Op CF | -41.8M | -40.0M | -36.3M | -21.7M | — | -50.0M | — | — | — |
| Inv CF | -24.6M | 25.0M | 32.0K | 75.0K | — | — | — | — | — |
| Fin CF | 53.7M | 11.9M | 10.2M | 26.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-7.9%
SMA 50SMA 200
Close
$28.00
RSI (14)
57.9
52W High
$45.50
From 52W High
0.6%
SCORE BREAKDOWN
Quality
12
ROIC
-89.6%7.6
ROE
-1603.5%0.3
GP/Assets
-88.4%0.3
Op. Margin
-1113.3%6.8
FCF/Assets
-35.3%10.7
Piotroski
559.7
Int. Cover
-50.0x5.9
D/E Ratio
1.33x9.7
Current Ratio
1.25x18.5
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-1.9x25.0
P/FCF
—N/A
P/B
62.1x1.4
P/S
5.3x40.2
Div Yield
—N/A
Momentum
63
52W High %
62%38.8
RS 6M
175%99.2
SMA 50/200
1.54x98.5
EPS Rev 4W
0.0%34.4
EPS Rev 12W
—N/A
EPS Improve
+98%73.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$203M
P/E (Forward)
-57.2x
Gross Margin
-2.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CUE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CUE | Cue Biopharma, Inc.(you) | $203M | 16 | Strong Sell |
| KRRO | Korro Bio, Inc. | $190M | 17 | Strong Sell |
| KROS | Keros Therapeutics, Inc. | $219M | 16 | Strong Sell |
| PEPG | PepGen Inc. | $213M | 14 | Strong Sell |
| VYGR | Voyager Therapeutics, Inc. | $218M | 14 | Strong Sell |
| CHRS | Coherus Oncology, Inc. | $218M | 14 | Strong Sell |
| ABOS | Acumen Pharmaceuticals, Inc. | $211M | 13 | Strong Sell |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $233M | 14 | Strong Sell |
| MGNX | MacroGenics, Inc. | $263M | 17 | Strong Sell |
| SPRB | Spruce Biosciences, Inc. | $175M | 13 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%